Al Mayadeen English

  • Ar
  • Es
  • x
Al Mayadeen English

Slogan

  • News
    • Politics
    • Economy
    • Sports
    • Arts&Culture
    • Health
    • Miscellaneous
    • Technology
    • Environment
  • Articles
    • Opinion
    • Analysis
    • Blog
    • Features
  • Videos
    • NewsFeed
    • Video Features
    • Explainers
    • TV
    • Digital Series
  • Infographs
  • In Pictures
  • • LIVE
News
  • Politics
  • Economy
  • Sports
  • Arts&Culture
  • Health
  • Miscellaneous
  • Technology
  • Environment
Articles
  • Opinion
  • Analysis
  • Blog
  • Features
Videos
  • NewsFeed
  • Video Features
  • Explainers
  • TV
  • Digital Series
Infographs
In Pictures
  • Africa
  • Asia
  • Asia-Pacific
  • Europe
  • Latin America
  • MENA
  • Palestine
  • US & Canada
BREAKING
Head of the Russian delegation to the talks in Turkey: The Russian-Ukrainian talks yielded good results.
Al Mayadeen's correspondent in occupied Palestine: Martyrs and wounded after an IOF aircraft bombed a house in Tal al-Zaatar, north of the Gaza Strip.
Libya: The Libyan Ministry of Health declares a state of maximum emergency in all hospitals to support medical staff working in Tripoli and its suburbs.
Libya: Demonstrations in several Libyan cities demand the overthrow of the Dbeibah government.
Italian Foreign Ministry: We are following developments in Libya with concern and reiterate our call for all parties to return to calm and dialogue.
Libya: Demonstration in Bani Walid calls for the overthrow of the Dbeibah government and holding it accountable.
Libya: Sabratha Municipal Council supports the overthrow of the Dbeibah government and calls on it to leave.
Al Mayadeen's correspondent in occupied Palestine: The IOF is carrying out massive bombing operations in the northern Gaza Strip.
Tunisian Foreign Ministry: We renew our call for an immediate end to the escalation in all parts of Libya.
Tunisian Ministry of Foreign Affairs: We express our deep concern over the dangerous security developments in the Libyan capital.

CAR T Cell Therapy reaches beyond cancer

  • By Al Mayadeen English
  • Source: Agencies
  • 24 Nov 2022 18:32
  • 1 Shares
4 Min Read

A Penn Medicine CAR T pioneer and a doctoral student in Cell and Molecular Biology discuss the development and progress in treating certain B cell leukemia, lymphoma, and other blood cancers.

  • x
  • CAR T Cell Therapy Reaches Beyond Cancer (Photo: Credit: Keith Chambers / Science Photo Library / Getty Images)
    Researchers have reported highly promising early results for CAR T therapy in a small group of patients with the autoimmune disease lupus. (Photo: Credit: Keith Chambers / Science Photo Library / Getty Images)

Chimeric antigen receptor cells (CAR T), or engineered immune cells, have revealed the ability of personalized immunotherapies to fight blood cancers. Now, researchers have reported highly promising early results for CAR T therapy in a small group of patients with the autoimmune disease lupus. Penn Medicine CAR T pioneer Carl June, MD, and Daniel Baker, a doctoral student in Cell and Molecular Biology in the Perelman School of Medicine at the University of Pennsylvania, discuss this progress in a commentary published today in Cell.

"We've always known that in principle, CAR T therapies could have broad applications, and it's very encouraging to see early evidence that this promise is now being realized," said June, who is the Richard W. Vague Professor in Immunotherapy in the department of Pathology and Laboratory Medicine at Penn Medicine and director of the Center for Cellular Immunotherapies at Penn's Abramson Cancer Center.

Read: Immunotherapy treatment "cures" 2 cancer patients

T cells are among the immune system's most powerful weapons. They can bind to and kill the cells they see as valid targets, including cells infected by viruses. CAR T cells are T cells that have been redirected to effectively kill specifically defined cell types, through genetic engineering.

How are CAR T therapies created?

The cells of each patient are what make CAR T therapies; they are collected from the patient's blood and engineered and multiplied in a lab before they are re-infused into the patient as a "living drug."

The first CAR T therapy, Kymriah, was developed by June and his team at Penn Medicine. It was approved by the Food and Drug Administration in 2017. There are now six FDA-approved CAR T cell therapies in the United States for six different cancers. The therapies have created a revolution in the treatment of certain B cell leukemia, lymphoma, and other blood cancers. Many patients who had little hope have now been put into long-term remission.

Since the beginning of the research, experts believed that T cells could be engineered to fight many conditions other than B cell cancers. These potential new applications are being examined by dozens of research teams around the globe.

The commentary from Baker and June comes in response to the first significant clinical report about the success resulting from these efforts: a paper in Nature Medicine by German researchers on the CAR T therapy used to fight the autoimmune disease lupus (systemic lupus erythematosus).

Lupus, according to researchers, is an obvious choice for CAR T therapy because it, too, is driven by B cells. Thus, experimental CAR T therapies can employ existing anti-B-cell designs. B cells are the immune system's antibody-producing cells, and, in lupus, B cells arise and attack the patient's own organs and tissues.

In the German study, the patients, five young adults, did not benefit from standard lupus treatments. Yet, they all went into remission and were able to stop taking their lupus drugs within three months of a single, relatively small dose of CAR T therapy, which essentially removed their existing B cells.

What was even more noticeable is that all the patients remained in remission during the follow-up period of up to a year, and unlike cancer patients, the lupus patients' B cells came back. They are naturally replenished from blood stem cells in the bone marrow.

June and Baker noted in their commentary that, although the German study's results should be confirmed with bigger studies and longer-term follow-up, they are significantly promising. They suggest that lupus could turn out to be an easier CAR T target than B-cell cancers.

"Disease-driving B cells are much less numerous in lupus," Baker said. "Thus, effective CAR T treatment of this autoimmune disease may require a much lower dose that greatly reduces the problem of immunological side-effects."

  • Cell Therapy
  • Car T
  • Cancer
  • Engineered immune cells

Most Read

Two F-35 jets arrive at it's new operational base Wednesday, Sept. 2, 2015, at Hill Air Force Base, in northern Utah. (AP)

F-35 near-misses over Yemen signal new risks for 'Israel': Forbes

  • Politics
  • 14 May 2025
Palestinians pray over bodies of people killed in the Israeli bombardment who were brought from the Shifa hospital before burying them in a mass grave in the town of Khan Younis, southern Gaza Strip, Wednesday, Nov. 22, 2023. (AP )

Gaza casualty figures mask a much bigger horror, new study shows

  • Politics
  • 11 May 2025
Gaza and the logic of necropolitics: Sovereignty measured by killing

Gaza and the logic of necropolitics: Sovereignty measured by killing

  • Politics
  • 15 May 2025
Abu Obaida

Abu Obeida posts shortly after Israeli reports about his assassination

  • Palestine
  • 15 May 2025

Coverage

All
Gaza prevails against genocide

Read Next

All
Israeli media: Yemen may push 'Israel' towards ceasefire in Gaza
MENA

Israeli media: Yemen may push 'Israel' towards ceasefire in Gaza

Palestinians struggle to get donated food at a community kitchen in Khan Younis, Gaza Strip, Friday, May 16, 2025 (AP)
Politics

Trump administration planning to send 1 million Palestinians to Libya

President Donald Trump greets Israeli Prime Minister Benjamin Netanyahu at the White House, Monday, April 7, 2025, in Washington. (AP)
Politics

'Israel' concerned, says US withholding info about indirect Iran talks

Israeli Prime Minister Benjamin Netanyahu during the annual ceremony at the Yad LaBanim Memorial in occupied al-Quds on Tuesday, April 29, 2025 (AP)
Politics

Netanyahu cancels Vatican visit over fears of ICC arrest

Al Mayadeen English

Al Mayadeen is an Arab Independent Media Satellite Channel.

All Rights Reserved

  • x
  • Privacy Policy
  • About Us
  • Contact Us
  • Authors
Android
iOS